Pharmaceuticals, Biotechnology and Life Sciences
Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.
Alliance Healthcare UK has appointed Paula Sutherland to the position of Sales Director where she will lead sales teams in…
Clinigen, the global pharmaceutical services company, today announces it has signed an exclusive supply and distribution agreement with Santhera Pharmaceuticals (SIX:…
Italian clinical-stage oncology company BetaGlue Therapeutics, developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, announced Monday that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m.
Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark.
Basilea Pharmaceutica, a Swiss bacterial and fungal infections biopharmaceutical specialist, has entered into an exclusive distribution and license agreement with…
Italian Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and Japanese EA Pharma, a subsidiary of Eisai Co., Ltd., have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories.
Each unit is being sold at an effective offering price of $5.85 per unit, priced at-the-market under Nasdaq rules.
US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade
NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the…